Email Medtest Medtest Headquarters Medtest Facebook Medtest Linkedin

Optimized Application Released For autoHDL™ and the Beckman AU 400 Analyzer

Aug 11, 2014 - news

The purpose of this advisory is to alert users of the Pointe Scientific autoHDL™ reagent (catalog #: OH945-480) and the Beckman AU 400, that optimized instrument parameters have been released.

The new application will provide optimized performance. The optimization was a revision in the primary and secondary wavelengths utilized. Please review the attached revised package insert and Instrument application reviewing Instrument Parameter settings closely.

When implementing a change in an application, users may notice a slight shift in their quality control data. Please incorporate this Bulletin into your Quality Control files.

For more information, follow this link.

MedTest introduces the Pointe Scientific Cystatin C Reagent

May 27, 2014 - press releases

For Immediate Release:  MedTest Introduces the Pointe Scientific Cystatin C1 Reagent

(Canton, Michigan) – MedTest introduces the Pointe Scientific Cystatin C1 Reagent.  The reagent is a latex-enhanced immunoturbidimetric assay for the quantitative determination of Cystatin C in human serum, heparinized-plasma, or EDTA-plasma. The reagent can be used on many automated clinical chemistry analyzers. The reagent kit with an assay range of 0.2 to 8.0 mg/L shows excellent correlation with other commercially available assays.

Cystatin C is mainly used as a biomarker of kidney function. Unlike creatinine results for estimating glomerular filtration rates (eGFR), Cystatin C is not dependent on age, sex, race, weight or other parameters.  It is widely published to be a better indicator of early kidney damage and can determine more accurately and more quickly any changes in renal function.  Recently, it has been reported that the use of Cystatin C alone or in combination with creatinine strengthens the association between eGFR and the risks of death and end-stage renal disease across diverse populations2.

About MedTest:  MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing.  In June 2013, MedTest acquired Pointe Scientific, a company that has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981.

For additional information, please visit www.pointescientific.com or contact:

Debbie Whitehair

Vice President, Marketing

484-748-1603

dwhitehair@medtest.com 

1   For Research Use Only in the USA. Not available for clinical human blood testing in the USA

2   Shlipak MG, et al, Cystatin C versus Creatinine in Determining Risk Based in Kidney Function, N Engl J Medicine 2013; 369: 932-43.

PR-C7584-01   05/14 

Martin Charles named Technical Service Manager at MedTest

Mar 28, 2014 - news

Ron Jamison, Vice President - Director of Technical Operations, has announced the elevation of Martin Charles to Technical Service Manager. Mr. Charles has worked as a Clinical Laboratory Technologist for over 20 years and has honorably served his country as a Medical Laboratory Specialist in the United States Army during the Persian Gulf War. Martin is currently a New York State Licensed Clinical Laboratory Technologist and is a University of West Florida graduate. 

Martin will lead MedTest's Technical Service team in achieving and maintaining the highest degree of customer satisfaction and technical service related to product installations and performance.

Everyone at MedTest congratulates Martin and wishes him much success.   

Announcing the promotion of Jenna Edgar to the position of QA Laboratory Supervisor

Feb 25, 2014 - news

MedTest, a leading global clinical diagnostics company, is very pleased to announce the appointment of Jenna Edgar to the position of Quality Assurance Laboratory Supervisor. Ms. Edgar has served for the past year and a half as a Laboratory Technician. Her promotion is in recognition of her exceptional performance and leadership skills. 

In her capacity as QA Laboratory Supervisor, Jenna will oversee daily laboratory operations and personnel, and lead the team in workflow related to product release and stability testing. "Under Jenna’s leadership, I am confident the QA Laboratory Team will play a major role in meeting MedTest's Quality Assurance needs and requirements, and achieving our growth objectives," said Ron Jamison, Vice President of Technical Operations with MedTest.

Jenna holds a Bachelors of Science Degree and has been an ASCP registered Clinical Laboratory Scientist for over 5 years.  

MedTest DX Introduces a Highly Complex Drug of Abuse Test Menu

Jan 2, 2014 - press releases

Mindray™ BS-200, Poly-Chem® 180, and Open Channel Applications

Canton, Michigan, January 2, 2014 – MedTest DX, A MedTest Company, is pleased to announce the introduction of a broad, highly complex drug of abuse menu for the Mindray™ BS-200 Chemistry Analyzer, the Poly-Chem® 180 Analyzer and as open channel applications on other clinical chemistry analyzers such as the Beckman Coulter AU instrument series in the United States. The introduction of this menu enables MedTest DX to provide high quality drug of abuse reagents to customers focused on pain management and drug abuse testing. 

Mindray™ BS-200 and Open Channel Applications

MedTest DX introduces 16 highly complex, urine drugs of abuse tests that include: 

6-Acetylmorphine, Amphetamine, Barbiturate, Benzodiazepine, Buprenorphine (Suboxone), Cannabinoid (THC), Cocaine Metabolite, Ecstasy (MDMA), Ethanol, Methadone, Methadone Metabolite (EDDP), Methamphetamine, Opiates, Oxycodone, Phencyclidine and Propoxyphene

Poly-Chem® 180

MedTest DX introduces 5 highly complex, urine drugs of abuse tests (6-Acetylmorphine, Buprenorphine, Oxycodone, Phencyclidine and Propoxyphene) to its existing 10 tests that make up the moderately complex test menu.

“Menu expansion enables MedTest DX to meet our customer’s needs in the pain management and drug abuse testing arena” said Hanjoon Ryu, CEO of MedTest.  “Our drugs of abuse offering on analyzers like the Mindray™ BS-200 enable our pain management clinic customers to implement a quality urine screening process while allowing our laboratory customers to minimize their overall cost and enhance their overall efficiency.”

For more information on MedTest DX’s urine drugs of abuse portfolio, please contact Debbie Whitehair at dwhitehair@medtestdx.com, Sales Support at 1.800.445.9853 or visit www.medtestdx.com 

 

PR-M2111-03   12/13

PREV 1 2 3 4 5 6 7 8 9 10 11 NEXT